Abstract
Petr Kocis earned his Ph.D. in organic and medicinal chemistry at the Czechoslovak Academy of Sciences, Prague, Czechoslovakia. He did his postdoctoral research with Prof. Jack Baldwin, the University of Oxford, England and worked with the Oxford Enzyme Group. During the last two decades he has been involved in drug discovery research in cancer, immunodeficiencies, asthma and drug lead discovery at Hoechst-Marion-Roussell, Zeneca Pharmaceuticals and AstraZeneca, lately as Associate Director, Global Enabling Science & Technologies, and Principle Scientist II. Dr. Kocis is one of the pioneers of combinatorial chemistry field, he helped to build Selectides combinatorial chemistry and technology in Tucson, Arizona, in the early 90s. In the mid 90s he co-build the US Chemical Technologies group at Zeneca Pharmaceuticals and co-developed a novel combinatorial chemistry that was industrialized within the International Lead Drug Discovery as a part of modern medicinal chemistry. He is a recipient of the R & D Directors Award for Creativity and Innovation by Zeneca, and a recipient of the Henry Christian Award for Excellence in Research by Merck. He is on the editorial board of several journals including Drugs of the Future and on the Scientific Advisory Board of Cambridge Healthtech Institute. Dr. Kocis is the author or coauthor of numerous articles, book chapters and patents. His research interest is multidimensional challenges of drug discovery, modern medicinal and combinatorial chemistry, visualization and data mining.
Current Drug Discovery Technologies
Title: About Editor-in-Chief
Volume: 1 Issue: 1
Abstract: Petr Kocis earned his Ph.D. in organic and medicinal chemistry at the Czechoslovak Academy of Sciences, Prague, Czechoslovakia. He did his postdoctoral research with Prof. Jack Baldwin, the University of Oxford, England and worked with the Oxford Enzyme Group. During the last two decades he has been involved in drug discovery research in cancer, immunodeficiencies, asthma and drug lead discovery at Hoechst-Marion-Roussell, Zeneca Pharmaceuticals and AstraZeneca, lately as Associate Director, Global Enabling Science & Technologies, and Principle Scientist II. Dr. Kocis is one of the pioneers of combinatorial chemistry field, he helped to build Selectides combinatorial chemistry and technology in Tucson, Arizona, in the early 90s. In the mid 90s he co-build the US Chemical Technologies group at Zeneca Pharmaceuticals and co-developed a novel combinatorial chemistry that was industrialized within the International Lead Drug Discovery as a part of modern medicinal chemistry. He is a recipient of the R & D Directors Award for Creativity and Innovation by Zeneca, and a recipient of the Henry Christian Award for Excellence in Research by Merck. He is on the editorial board of several journals including Drugs of the Future and on the Scientific Advisory Board of Cambridge Healthtech Institute. Dr. Kocis is the author or coauthor of numerous articles, book chapters and patents. His research interest is multidimensional challenges of drug discovery, modern medicinal and combinatorial chemistry, visualization and data mining.
Export Options
About this article
Cite this article as:
About Editor-in-Chief, Current Drug Discovery Technologies 2004; 1 (1) . https://dx.doi.org/10.2174/1570163043484842
DOI https://dx.doi.org/10.2174/1570163043484842 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) Prediction by Pharmacogenetics of Safety and Efficacy of Non-Steroidal Anti- Inflammatory Drugs: A Review
Current Drug Metabolism Cyclic Nucleotide and Protein Kinase Signaling in Hypertensive Pulmonary Arterial Smooth Muscle
Current Respiratory Medicine Reviews Interleukin 20
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry siRNA as a Potential Therapy for COVID-19
Current Drug Delivery Treatment of Disorders Characterized by Reversible Airway Obstruction in Childhood: are Anti-cholinergic Agents the Answer?
Current Pharmaceutical Design Pharmacological Regulation of Human Eosinophil Apoptosis
Current Drug Targets - Inflammation & Allergy Inhibition of Mitogen-Activated Protein Kinases (MAPKs) as a Strategy to Prevent Intimal Hyperplasia Following Cardiovascular Interventions
Vascular Disease Prevention (Discontinued) Cow’s Milk Allergy in Children, from Avoidance to Tolerance
Endocrine, Metabolic & Immune Disorders - Drug Targets Viral Bronchiolitis and Asthma Development: Lessons from Longitudinal Studies
Current Respiratory Medicine Reviews Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain
Current Medicinal Chemistry - Central Nervous System Agents Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets New Patents of Fixed Combinations of Nasal Antihistamines and Corticosteroids in Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Chemokines and Receptors as Targets in Anti-Inflammatory Therapy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Collaborative Edge-Cloud Internet of Things Based Framework for Securing the Indian Healthcare System
International Journal of Sensors, Wireless Communications and Control